+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 30 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating YL205, a drug given by intravenous infusion, in patients with advanced solid tumors. This multicenter, open-label phase III study in China aims to assess the safety, tolerability, pharmacokinetics how the drug moves through the body, and preliminary effectiveness of YL205. Eligible patients have advanced solid tumors that overexpress Napi2B and include cancers such as ovarian, non-squamous non-small cell lung, renal cell, and endometrial cancer. Participants receive YL205 as a lyophilized powder reconstituted for intravenous infusion at a dose of 160 mg per vial. Treatment is given once every three weeks in cycles, with dose levels adjusted during different study phases dose escalation phase Ia, dose expansion phase Ib, and cohort expansion phase II. The study evaluates at least two dose levels and the recommended phase 2 dose RP2D. Throughout approximately 36 months, participants are closely monitored for dose-limiting toxicities, treatment-emergent adverse events, and serious adverse events. Researchers assess tumor response using RECIST v1.1 criteria, including overall response rate, disease control rate, duration and depth of response, progression-free survival, and overall survival. Pharmacokinetic parameters like AUC, Cmax, and half-life are also measured. Patients undergo tumor sampling and radiological evaluations to track treatment effects and safety.

Age: 18Years +All GendersPhase 1Phase 2
43 locations
P

Actively Recruiting

Researchers are conducting a Phase 1 study to evaluate BHV-1530 alone and in combination with cemiplimab in adults with advanced or metastatic solid tumors. This first-in-human, open-label trial aims to determine the safety, dosing, and potential benefits of BHV-1530 for patients whose cancer has progressed after standard treatments or who have no other available therapies. The study focuses on specific cancers including urothelial cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma, especially those with certain genetic alterations. Participants will receive BHV-1530 as an intravenous infusion on Day 1 of each 21-day cycle, either alone or combined with cemiplimab given on the same schedule. The study includes dose escalation, expansion, and optimization phases to find the maximum tolerable dose and recommended dose range. Some groups may receive the drug alone, while others receive it combined with cemiplimab, with treatment continuing over multiple cycles as determined by the study protocol. During the trial, participants will have regular assessments to monitor safety and treatment effects, including tumor measurements according to RECIST 1.1 criteria and performance status evaluations. Researchers will collect tumor tissue samples, perform laboratory tests, and monitor drug levels in the blood. The main outcomes include determining optimal dosing, safety profile, and clinical benefit rates over an estimated 48 months. Participants health and response to treatment will be carefully followed throughout the study period.

Age: 18Years +All GendersPhase 1
17 locations
O

Actively Recruiting

Researchers are studying FMC-376 alone and combined with pembrolizumab in adults with advanced solid tumors that have the KRAS G12C mutation. This clinical trial includes three parts Phase 1A Dose Escalation, Phase 1B Dose Expansion, and Phase 2 Cohort Expansion. It aims to evaluate multiple dose levels and assess safety, pharmacokinetics, and clinical activity in participants with these tumors. Participants will receive FMC-376 orally daily in 21-day cycles, either as monotherapy or combined with pembrolizumab. The study progresses sequentially through dose escalation, dose expansion, and cohort expansion stages to find appropriate dosing and evaluate effects. Those receiving combination therapy must meet additional criteria related to immune health. Throughout the trial, participants will be closely monitored for dose limiting toxicities, adverse events, and overall response over approximately 24 months. Researchers will assess drug levels in blood, response duration, disease control, progression-free and overall survival. The study ensures safety and compliance by evaluating participants health status and organ function regularly.

Age: 18Years +All GendersPhase 1Phase 2
26 locations
P

Actively Recruiting

Researchers are evaluating ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. This Phase 1 open-label study aims to assess how safe and tolerable ASP3082 is when given alone or with other treatments like cetuximab. The study includes people who have received prior standard therapies or are ineligible for them, focusing on determining appropriate doses and treatment combinations. The study is divided into two parts. In Part 1, small groups of participants receive increasing doses of ASP3082 alone or with cetuximab through intravenous infusion in 21-day cycles to find suitable dosing levels. In Part 2, participants receive ASP3082 alone or combined with other therapies such as FOLFIRINOX, Nab-paclitaxel plus gemcitabine, docetaxel, pembrolizumab, platinum-based chemotherapy with pemetrexed, or NALIRIFOX, with dosing based on Part 1 findings. Treatment continues until intolerable side effects, disease progression, starting other cancer treatments, or participant decision to stop. Participants will undergo regular assessments including monitoring for side effects, laboratory tests, electrocardiograms, physical exams, and performance status evaluations for up to 48 months. Researchers will measure dose-limiting toxicities, adverse events, and tumor response using standard criteria. Tumor samples will be collected before and during treatment to assess KRAS G12D changes. The study monitors safety and treatment effects closely throughout participation, which may last several years.

Age: 18Years +All GendersPhase 1
68 locations
S

Actively Recruiting

Researchers are evaluating the safety, toxicity, and pharmacokinetics of BTX-A51, alone and combined with fulvestrant, in people with advanced solid tumors and metastatic breast cancer that is estrogen receptor positive and HER2 negative. This phase 1, open-label study aims to find the safe dose levels and observe preliminary effects of the treatments in this patient group. The study includes multiple phases to carefully assess dosing and safety. The study has three phases. Phase 1a is a dose escalation phase where BTX-A51 is taken orally once daily on a schedule of 5 days on and 2 days off, in 28-day cycles. Dose levels increase sequentially to find the maximum tolerated dose. Phase 1b involves dose ranging of BTX-A51 alone in patients with specific breast cancer mutations, with dosing over 28 days. Phase 1c tests BTX-A51 combined with fulvestrant, an injection given on specific days within 28-day cycles, to evaluate combined safety. Participants will take BTX-A51 orally and may receive fulvestrant by injection if in the combination phase. Researchers will monitor adverse events, dose tolerance, and drug levels in the blood, collecting blood samples at specific times during treatment cycles. They will also assess response rates, duration of response, progression-free survival, and overall survival for up to two years after treatment. Safety follow-up continues for 30 days post-treatment, with options for continued access to BTX-A51 until disease progression or unacceptable toxicity.

Age: 18Years +All GendersPhase 1
6 locations
S

Actively Recruiting

Researchers are evaluating LY4050784, a selective SMARCA2BRM inhibitor, in adults with advanced or metastatic solid tumors that have alterations in the SMARCA4 BRG1 gene. This includes patients who have previously received or are not candidates for standard treatments, or for whom no standard therapy exists. The study is conducted in two phases phase Ia focuses on dose escalation, and phase Ib on dose optimization and dose expansion, lasting up to about four years. Participants receive oral doses of LY4050784 alone or combined with other anticancer drugs such as pembrolizumab, pemetrexed, cisplatin, carboplatin, paclitaxel, or nab-paclitaxel. Treatments are given in 21-day cycles, and participants may continue treatment until criteria for stopping are met. The study compares different doses during phase Ia and assesses safety and efficacy during phase Ib, including both monotherapy and combination therapy groups. Throughout the study, participants undergo regular assessments to monitor safety, side effects, and antitumor activity, including response rates and disease control. Researchers also measure drug levels in the body and other pharmacokinetic properties. The safety and tolerability of LY4050784 alone and in combination are evaluated over approximately four years, with ongoing monitoring of adverse events and tumor response.

Age: 18Years +All GendersPhase 1
32 locations
P

Actively Recruiting

Researchers are evaluating oral Alintegimod 7HP349 alone and in combination with ipilimumab, followed by nivolumab monotherapy, in patients with locally advanced or metastatic cancers who have received one or more prior therapies. This open-label Phase Ib dose escalation study is followed by a blinded, randomized multi-cohort Phase 2a comparison of combination versus reference regimens, aiming to assess safety, tolerability, and preliminary efficacy. Participants will receive Alintegimod monotherapy in escalating doses for one cycle, then Alintegimod combined with ipilimumab for four cycles, followed by nivolumab monotherapy for eleven cycles. Alintegimod is given orally as softgel capsules, while ipilimumab and nivolumab are administered intravenously. The treatment continues until the end of the study period, lasting 12 months, unless disease progression or toxicity requires early termination. Throughout the study, participants will undergo assessments including adverse event monitoring, pharmacokinetic testing, and tumor response evaluations using RECIST criteria. Researchers will measure treatment-related side effects, drug levels in the blood, progression-free survival, and overall response rates. Safety will be closely monitored over 18 months, with participants expected to attend regular visits for clinical evaluations and laboratory tests during the study duration.

Age: 18Years +All GendersPhase 1Phase 2
5 locations
S

Actively Recruiting

Researchers are evaluating the safety, tolerability, and preliminary effectiveness of EIK1004 IMP1707, a PARP1 selective inhibitor, in adults with advanced solid tumors including recurrent advancedmetastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer mCRPC, and pancreatic cancer. These participants must have mutations in select homologous recombination repair HRR genes. The study is a Phase 12 open-label trial sponsored by Eikon Therapeutics. The study has two parts dose escalation and dose optimization. In the dose escalation phase, participants receive escalating oral doses of EIK1004 daily except during a single-dose period to find the highest tolerated or achievable dose. The dose optimization phase further evaluates safety, tolerability, how the drug moves and acts in the body, and anti-tumor effects at selected doses. Participants will be monitored closely with assessments including adverse event tracking up to one month after the last dose, and pharmacokinetic evaluations up to three years. The main outcomes include the number of participants experiencing dose-limiting toxicities and other adverse events. Participants must have evaluable disease and meet specific health and organ function requirements. The total study participation duration varies, with follow-up extending up to three years for some measures.

Age: 18Years - 89YearsAll GendersPhase 1Phase 2
10 locations
R

Actively Recruiting

Researchers are studying Raludotatug Deruxtecan R-DXd, an antibody-drug conjugate that targets CDH6 protein, in people with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. This trial includes a Phase 2 dose-optimization part to find the best dose based on safety and effectiveness, followed by a Phase 3 part comparing R-DXd to chemotherapy chosen by the investigator. Participants will receive R-DXd through an intravenous infusion every three weeks at varying doses during Phase 2. In Phase 3, participants will be randomly assigned to receive either R-DXd at the recommended dose or one of the chemotherapy options paclitaxel, pegylated liposomal doxorubicin PLD, or topotecan, also given intravenously every three weeks. During the study, participants will undergo scans and biopsies to evaluate tumor response and drug effects. Researchers will monitor safety, side effects, and various measures such as progression-free survival and overall survival for up to 40 months. Participants will have regular visits for treatment, assessments, and laboratory tests to track their health and response to the study treatments.

Age: 18Years +All GendersPhase 2Phase 3
167 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an investigational mRNA seasonal flu vaccine compared to a licensed flu vaccine in adults aged 65 years and older. The study aims to assess the ability of the vaccines to prevent laboratory-confirmed influenza illness, monitor side effects, and measure immune responses during the flu season. This Phase 3 randomized, observer-blind trial is sponsored by GlaxoSmithKline and focuses on flu prevention in older adults. Participants will receive a single injection on Day 1 of either the investigational mRNA seasonal flu vaccine or a licensed, age-appropriate, season-adapted influenza vaccine. The study follows a parallel group design where participants are randomly assigned to one of these two vaccine groups. The follow-up period covers the entire influenza season to assess vaccine efficacy and safety. During the study, participants will be monitored for influenza-like illness confirmed by laboratory tests from Day 15 through the end of the influenza season. Safety assessments include tracking solicited local and systemic side effects from Day 1 to Day 7, unsolicited adverse events up to Day 28, and serious adverse events or special interest adverse events through at least 180 days of follow-up. Blood samples will be collected before dosing and on Day 29 to evaluate immune responses. Participants are followed for safety and efficacy throughout the flu season, with total involvement spanning several months.

Age: 65Years +All GendersPhase 3
163 locations

1-10 of 30

1